Aduro's (ADRO) Earnings & Revenues Miss Estimates In Q4

Shares of Aduro BioTech, Inc. (NASDAQ:ADRO) were down 16.3% on Tuesday following its earnings release on Monday. In fact, the stock has plunged 37.1% in the past year compared to the industry’s decrease of 12.5%.

Aduro incurred fourth-quarter 2019 loss of 24 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents but narrower than the year-ago loss of 33 cents.

Revenues of $3.6 million were up 31.7% year over year, primarily owing to ratalable recognition of an upfront payment received in 2019 under the collaboration with Eli Lilly (NYSE:LLY) . Notably, in December 2018, Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.

However, sales missed the Zacks Consensus Estimate of $5 million.

Quarter in Detail

Research and development expenses declined 14.2% in the reported quarter to $15.1 million due to lower stock-based compensation and headcount costs resulting from the strategic reset in January 2019.

We remind investors that in January 2019, Aduro announced a strategic reset to focus primarily on the discovery and development of novel product candidates in the STING and APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases. Following this, the company reduced its workforce by almost 37%.

Moreover, in January 2020, Aduro announced a corporate restructuring to extend its operating capital and align personnel with the execution of clinical development strategy. As part of this, the company trimmed its current workforce by 51 employees across the organization and expects to shut down its Europe headquarters in Oss, The Netherlands by the end of third-quarter 2020.

General and administrative expenses were $9 million, flat year over year.

Aduro had $213.6 million worth of cash, cash equivalents and marketable securities as of Dec 31, 2019 compared with $235.4 million on Sep 30, 2019.

Full-Year Results

For 2019, Aduro’s revenues of $17.3 million were up 14.4% year over year.

Loss per share was $1.03 in 2019 compared with the loss of $1.21 in 2018.

Pipeline & Other Updates

Aduro’s lead pipeline candidates are STING pathway activator ADU-S100 and anti-APRIL antibody BION-1301.

The company has a collaboration and license deal with Novartis (NYSE:NVS) for developing ADU-S100. The candidate is being evaluated in a phase I study as a monotherapy in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro is also conducting a phase Ib study to assess ADU-S100 in combination with Novartis’ anti-PD-1 monoclonal antibody spartalizumab for the same indication.

Further, the company is evaluating ADU-S100 in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab) in a phase II study for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Meanwhile, last month, Aduro earned a development milestone fee of $10 million under its licensing agreement with Merck for initiating a phase II study on MK-5890, an anti-CD27 agonist, for treating non-small cell lung cancer (NSCLC).

Notably, Aduro is currently evaluating BION-1301 in a phase I clinical study for treating IgA nephropathy in healthy volunteers. The company plans to begin dosing IgA nephropathy patients in the first half of 2020.

Aduro Biotech, Inc. Price, Consensus and EPS Surprise

Aduro Biotech, Inc. Price, Consensus and EPS Surprise

Aduro Biotech, Inc. price-consensus-eps-surprise-chart | Aduro Biotech, Inc. Quote

Zacks Rank

Aduro currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>